PCSK9 Inhibitor Market Outlook 2034: Surging at 16.9% CAGR to Reach US$ 9.3 Billion
The global PCSK9 inhibitor market is entering a transformative decade marked by robust growth, expanding clinical applications, and intensifying competition among leading biopharmaceutical innovators. PCSK9 inhibitors, a class of monoclonal antibodies and novel lipid-lowering agents designed to reduce low-density lipoprotein cholesterol (LDL-C), have rapidly emerged as a cornerstone therapy for...
0 Комментарии 0 Поделились 84 Просмотры 0 предпросмотр
Спонсоры